Investigational drug · Phase 3
Oteracil Potassium
Also called: gimeracil], S-1 [Tegafur
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Biliary Tract Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasms of Digestive Organs.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
94
Any phase or sponsor naming "Oteracil Potassium"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Oteracil Potassium", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer
- Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Malignant Neoplasms of Digestive Organs
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Oteracil Potassium" as an intervention, largest first.
- Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by SurgeryPivotal-lookingCompleted
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
NCT00660894 · 1,535 participants · Start Apr 2008 · Primary completion Jun 2012
Drug: folinate calcium; tegafur-uracil and 1 more · For: Colorectal Cancer
Sites: Tokyo, Japan
- SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer PatientsPivotal-lookingStatus unknown
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT03448549 · 1,191 participants (planned) · Start Jan 1, 2018 · Primary completion Jan 1, 2021
Drug: Oxaliplatin; Tegafur,gimeracil and oteracil potassium and 1 more · For: Colorectal Cancer Stage III; Adjuvant Chemotherapy
Sites: Beijing, China
- Study of Adjuvant ONO-4538 With Resected Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT03006705 · 800 participants · Start Jan 31, 2017 · Primary completion Aug 17, 2022
Drug: Nivolumab; Tegafur-gimeracil-oteracil potassium and 3 more · For: Gastric Cancer
Sites: Anhui Province, China; Beijing, China; Cuangdong Province, China · 108 sites in all
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaPivotal-lookingRecruiting
AkesoIndustry
NCT07023315 · 760 participants (planned) · Start Aug 14, 2025 · Primary completion Jul 2029
Drug: Cadonilimab; SOX chemotherapy and 1 more · For: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Sites: Beijing, China; Fuzhou, China; Shijiazhuang, China · 6 sites in all
- Perioperative Chemotherapy for Potentially Resectable Gastric CancerPivotal-lookingCompleted
Hebei Medical UniversityAcademic, hospital or other
NCT01516944 · 749 participants · Start Feb 2012 · Primary completion Apr 2018
Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin; Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin and 1 more · For: Gastric Cancer
Sites: Shijiazhuang, China
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07643623 · 720 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 31, 2031
Drug: tegafur, Gimeracil and Oteracil Potassium Capsules; Sintilimab Placebo and 4 more · For: Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Sites: Guangzhou, China
- Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer PatientsPivotal-lookingNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05498766 · 702 participants (planned) · Start Jul 1, 2024 · Primary completion Jul 1, 2029
Drug: Huaier granule; Oxaliplatin and 1 more · For: Gastric Cancer
Sites: Wuhan, China; Qingdao, China
- Study of ONO-4538 in Gastric CancerPivotal-lookingCompleted
Ono Pharmaceutical Co., Ltd.Industry
NCT02746796 · 680 participants (planned) · Start Mar 2016 · Primary completion Jan 2020
Drug: ONO-4538; Oxaliplatin and 3 more · For: Gastric Cancer
Sites: Nagoya, Japan; Hirosaki, Japan; Misawa, Japan · 130 sites in all
- The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic CancerRecruiting
Xi'an Jiaotong UniversityAcademic, hospital or other
NCT06368063 · 642 participants (planned) · Start May 6, 2024 · Primary completion Mar 2026
Drug: Huaier granule; chemotherapy drugs · For: Pancreatic Cancer Resectable
Sites: Xi'an, China
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT05934331 · 632 participants (planned) · Start Jul 27, 2023 · Primary completion Aug 6, 2031
Drug: LM-302; Toripalimab and 9 more · For: Malignant Neoplasms of Digestive Organs
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Multifocal primary hepatic small cell neuroendocrine carcinoma treated with sequential systemic therapies.
Inada H, Tanaka K, Yoshinari M, et al. · Clin J Gastroenterol 2026
- S1PR2 antagonist S118 prevents rapid degradation of 5-FU through down-regulation of hepatic dihydropyrimidine dehydrogenase (DPD).
Pan T, Fang HX, Yang M, et al. · Mol Cell Biochem 2026
- Prospective evaluation of combination oral S-1 and intravenous cisplatin in cancer patients with severe hepatic dysfunction - a feasibility, safety, and pharmacokinetic study.
Gwee YX, Wong ALA, Goh BC, et al. · Front Oncol 2026
- Exceptionally Durable Response to First-Line S-1 Monotherapy in Metastatic Pancreatic Adenocarcinoma: A Case Report.
Ota T, Iinuma S, Suyama Y · Cureus 2026
- Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from Japan.
Hironaka S, Kimijima Y, Shinno Y, et al. · Adv Ther 2026
- Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan.
Sanno H, Ito Y, Taniguchi K, et al. · Expert Rev Anticancer Ther 2026
Also in development for Biliary Tract Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.